Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular

trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/ flutter (AF/AFL). ATHENA was the first trial to demonstrate a CV outcomes benefit, specifically reduced CV hospitalizations, with an antiarrhythmic drug. The objective of this study was to assess the impact of dronedarone treatment on healthcare resource utilization among real-world patients with AF/AFL in United States clinical practice. Methods: This retrospective cohort study used claims data from the MarketScan databases (Truven Health, Durham, NC, USA) to identif